CoChat

Creatine supplementation improves neural progenitor cell survival in Huntington's disease

Open access
Widmer, HansR, Andres, RobertH, Wallimann, Theo · 2016 · Brain Circulation
Cited by 14

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Preclinical and clinical studies suggest that striatal transplantation of neural stem cells (NSCs) and neural progenitor cells (NPCs) may be an appealing and valuable system for treating Huntington's disease. Nevertheless, for a neural replacement to become an effective translational treatment for Huntington's disease, a certain number of difficulties must be addressed, including how to improve the integration of transplanted cell grafts with the host tissue, to elevate the survival rates of transplanted cells, and to ensure their directed differentiation into specific neuronal phenotypes. Research focusing on the translational applications of creatine (Cr) supplementation in NSC and NPC cell replacement therapies continues to offer promising results, pointing to Cr as a factor with the potential to improve cell graft survivability and encourage differentiation toward GABAergic phenotypes in models of striatal transplantation. Here, we evaluate research examining the outcomes of Cr supplementation and how the timing of supplementation regimes may affect their efficacy. The recent studies indicate that Cr's effects vary according to the developmental stage of the cells being treated, noting the dynamic differences in creatine kinase expression over the developmental stages of differentiating NPCs. This research continues to move Cr supplementation closer to the widespread clinical application and suggests such techniques warrant further examination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/2394-8108.192519

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 50

  1. Nayak, 2011, Huntington's disease: An immune perspective, Neurol Res Int, 563784
  2. Sanberg, 1984, Scientific approaches to Huntington's disease, CRC Crit Rev Clin Neurobiol, 1
  3. Hefter, 1987, Impairment of rapid movement in Huntington's disease, Brain, 585
  4. A, 1993, The Huntington's Disease Collaborative Research Group, Cell, 971
  5. Deckel, 1983, Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants, Eur J Pharmacol, 287
  6. Dunnett, 1988, Striatal grafts in rats with unilateral neostriatal lesions – III.Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching, Neuroscience, 813
  7. Isacson, 1986, Graft-induced behavioral recovery in an animal model of Huntington disease, Proc Natl Acad Sci U S A, 2728
  8. McBride, 2004, Human neural stem cell transplants improve motor function in a rat model of Huntington's disease, J Comp Neurol, 211
  9. Roberts, 2006, Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease, Neuroscience, 1187
  10. Aubry, 2008, Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats, Proc Natl Acad Sci U S A, 16707
  11. Kordower, 1997, Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease, J Comp Neurol, 96
  12. Bachoud-Lévi, 2000, Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease, Exp Neurol, 194
  13. Bachoud-Lévi, 2000, Motor and cognitive improvements in patients with Huntington's disease after neural transplantation, Lancet, 1975
  14. Freeman, 2000, Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology, Proc Natl Acad Sci U S A, 13877
  15. Hauser, 2002, Bilateral human fetal striatal transplantation in Huntington's disease, Neurology, 687
  16. Gallina, 2010, Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation, Exp Neurol, 30
  17. Bachoud-Lévi, 2006, Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: A long-term follow-up study, Lancet Neurol, 303
  18. Reuter, 2008, Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease, J Neurol Neurosurg Psychiatry, 948
  19. Wallimann, 1998, Creatine kinase: An enzyme with a central role in cellular energy metabolism, MAGMA, 116
  20. Andres, 2008, Functions and effects of creatine in the central nervous system, Brain Res Bull, 329
  21. Calabresi, 2001, Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine, J Neurosci, 5110
  22. Aronin, 1995, CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain, Neuron, 1193
  23. Andres, 2016, The effects of creatine supplementation on striatal neural progenitor cells depend on developmental stage, Amino Acids, 1913
  24. Andres, 2005, Effects of creatine treatment on survival and differentiation of GABA-ergic neurons in cultured striatal tissue, J Neurochem, 33
  25. Andres, 2010, Creatine improves the metabolic state of murine and human neural stem cells and improves expansion and neuronal induction, Regen Med, 2
  26. Verbessem, 2003, Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial, Neurology, 925
  27. Rosas, 2014, PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease, Neurology, 850
  28. Ohtsuki, 2002, The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain, J Cereb Blood Flow Metab, 1327
  29. Shao, 2006, Risk assessment for creatine monohydrate, Regul Toxicol Pharmacol, 242
  30. Slosman, 2001, Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention, Brain Res Brain Res Rev, 230
  31. Schlattner, 2006, Mitochondrial creatine kinase in human health and disease, Biochim Biophys Acta, 164
  32. Aksenov, 2000, Oxidative modification of creatine kinase BB in Alzheimer's disease brain, J Neurochem, 2520
  33. Wallimann T, Tokarska-Schlattner M, Neumann D, Epand RM, Epand RF, Hornemann T, et. al. The phosphocreatine circuit: Molecular and cellular physiology of creatine kinases, sensitivity to free radicals, and enhancement by creatine supplementation. In: Saks V, editor. Molecular System Bioenergetics: Energy for Life. Weinheim: Wiley-VCH Verlag GmbH & Co.; 2007. p. 195-264. · DOI · Paper page
  34. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 2002. p. 93-113.
  35. Schulze, 2003, Creatine deficiency syndromes, Mol Cell Biochem, 143
  36. Lin, 2013, Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease, Biochim Biophys Acta, 742
  37. Bürklen, 2006, The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits, J Biomed Biotechnol, 35936
  38. Braissant, 2002, Ammonium-induced impairment of axonal growth is prevented through glial creatine, J Neurosci, 9810
  39. Ducray, 2007, Creatine promotes the GABAergic phenotype in human fetal spinal cord cultures, Brain Res, 50
  40. Bourdelas, 2009, Dynamic expression pattern of distinct genes in the presomitic and somitic mesoderm during Xenopus development, Int J Dev Biol, 1075
  41. Watts, 1997, Effect of embryonic donor age and dissection on the DARPP-32 content of cell suspensions used for intrastriatal transplantation, Exp Neurol, 271
  42. Watts, 2000, Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease, Exp Neurol, 85
  43. Matthews, 1998, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease, J Neurosci, 156
  44. Shear, 2000, Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats, Neuroreport, 1833
  45. Andres, 2005, Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue, Neuroscience, 701
  46. Andres, 2005, Creatine supplementation improves dopaminergic cell survival and protects against MPP+ toxicity in an organotypic tissue culture system, Cell Transplant, 537
  47. Klivenyi, 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat Med, 347
  48. Klivenyi, 2004, Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis, J Neurochem, 576
  49. Dupuis, 2004, Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model, Proc Natl Acad Sci U S A, 11159
  50. Zhang, 2003, Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS, Ann Neurol, 267

Cited by

See all 14

Metadata

Authors
Widmer, H., Andres, R., & Wallimann, T.
Venue
Brain Circulation
Publisher
Medknow
Published
2016
Volume
2
Issue
3
Pages
133
ISSN
2394-8108 (ISSN-L)
OpenAlex
W2534060727
Cited by
14
References
8
FWCI
0.29
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Creatine supplementation improves neural progenitor cell survival in Huntington's disease. https://app.cochat.ai/papers/10.4103/2394-8108.192519
The paper
Widmer, H., Andres, R., & Wallimann, T. (2016). Creatine supplementation improves neural progenitor cell survival in Huntington's disease. Brain Circulation. https://doi.org/10.4103/2394-8108.192519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.